New antiplatelet and anticoagulant drugs. Considerations for dental patient management.

Harold V Cohen, Samuel Y P Quek, Gayathri Subramanian, Ali Abbas

UMDNJ-New Jersey Dental School, USA.

Journal of the New Jersey Dental Association 2013

filter terms:

A recent occurrence in dental practice is the noting of new "blood thinners" when the clinician is reviewing a patient's medical history and medications. "Doc, I take Pradaxa or Effient or Xarelto" etc. After many years of the widespread use of aspirin and Coumadin there has appeared a new generation of medications focused on reducing thromboembolic events in patients at risk. This trend has been driven by a need for drugs providing better drug efficacy based on patient biologic processing of the medications and the frequency and cost factors associated with the monitoring the degree of anticoagulation. Guidelines for assessing bleeding risk and managing patients on these new medications in dental practice are not yet defined and are empirically based on medical practitioner experience. This paper will review these new medications and will discuss current considerations for dental patient care. (Note that not all new antiplatelet and anticoagulant medications will be reviewed in this paper.)

Citation

Harold V Cohen, Samuel Y P Quek, Gayathri Subramanian, Ali Abbas. New antiplatelet and anticoagulant drugs. Considerations for dental patient management. Journal of the New Jersey Dental Association. 2013;84(1):30-3